TEVOGEN BIO HOLDINGS INC (TVGN) Stock Price & Overview
NASDAQ:TVGN • US88165K2006
Current stock price
The current stock price of TVGN is 7.55 USD. Today TVGN is up by 7.7%. In the past month the price increased by 58.61%. In the past year, price decreased by -84.78%.
TVGN Key Statistics
- Market Cap
- 31.408M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
TVGN Stock Performance
TVGN Stock Chart
TVGN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TVGN. When comparing the yearly performance of all stocks, TVGN is a bad performer in the overall market: 98.15% of all stocks are doing better.
TVGN Earnings
TVGN Forecast & Estimates
6 analysts have analysed TVGN and the average price target is 102 USD. This implies a price increase of 1250.99% is expected in the next year compared to the current price of 7.55.
TVGN Groups
Sector & Classification
TVGN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TVGN Ownership
TVGN Latest News, Press Relases and Analysis
TVGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 355.432B | ||
| AMGN | AMGEN INC | 15.09 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.44 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.23 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TVGN
Company Profile
Tevogen Bio Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Warren, New Jersey and currently employs 18 full-time employees. The company went IPO on 2021-11-04. Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The firm is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
Company Info
IPO: 2021-11-04
TEVOGEN BIO HOLDINGS INC
15 Independence Boulevard, Suite #210
WARREN NEW JERSEY US
Employees: 18
Phone: 16468078832
TEVOGEN BIO HOLDINGS INC / TVGN FAQ
What does TVGN do?
Tevogen Bio Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Warren, New Jersey and currently employs 18 full-time employees. The company went IPO on 2021-11-04. Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The firm is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
Can you provide the latest stock price for TEVOGEN BIO HOLDINGS INC?
The current stock price of TVGN is 7.55 USD. The price increased by 7.7% in the last trading session.
What is the dividend status of TEVOGEN BIO HOLDINGS INC?
TVGN does not pay a dividend.
How is the ChartMill rating for TEVOGEN BIO HOLDINGS INC?
TVGN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the employee count for TVGN stock?
TEVOGEN BIO HOLDINGS INC (TVGN) currently has 18 employees.
What is the market capitalization of TVGN stock?
TEVOGEN BIO HOLDINGS INC (TVGN) has a market capitalization of 31.41M USD. This makes TVGN a Nano Cap stock.
What is the next earnings date for TVGN stock?
TEVOGEN BIO HOLDINGS INC (TVGN) will report earnings on 2026-05-12.